FHTX — Foghorn Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $251.09m
- $70.81m
- $22.60m
Annual income statement for Foghorn Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.43 | 1.32 | 19.2 | 34.2 | 22.6 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 69.2 | 103 | 136 | 142 | 125 |
| Operating Profit | -68.8 | -102 | -117 | -108 | -103 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -68.8 | -101 | -109 | -94.2 | -86.6 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -68.8 | -101 | -109 | -98.4 | -86.6 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -68.8 | -101 | -109 | -98.4 | -86.6 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -68.8 | -101 | -109 | -98.4 | -86.6 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.86 | -2.69 | -2.62 | -2.34 | -1.53 |